# Evidence Flow Bottleneck Review 001

Objective: map where hypotheses stall between Hypothesis, Candidate, Paper Observation, Outcome, Validation Sample, and Evidence Maturity.

Scope: existing evidence only. This review adds no architecture, schemas, mechanisms, rule changes, sleeve changes, candidate-generation changes, governance changes, runtime truth changes, trade advice, candidates, or implementation.

Pinned evidence day: 2026-06-03.

Inputs:
- `outcome_bottleneck_decomposition_review_001.md`
- `outcome_maturity_acceleration_review_001.md`
- `root_cause_review_001.md`
- `journal_review_001.md`
- `journal_review_002.md`
- Sleeve throughput diagnostics and scorecard for 2026-06-03
- Candidate diagnostics for 2026-06-03
- Candidate-to-paper lifecycle for 2026-06-03
- Paper position ledger for 2026-06-03
- Validation sample summary for 2026-06-03
- Sleeve evidence certification for 2026-06-03

## Evidence Base

- Verified runtime graph for 2026-06-03: `graph_status` READY.
- Sleeve throughput evidence classification scorecard: 10 sleeves, with 5 FLOWING, 4 HEALTHY_NO_CANDIDATE, 1 NEEDS_DATA, 0 NEEDS_REPAIR, and 0 NEEDS_GOVERNANCE.
- Candidate diagnostics: 8 sleeves run, 42 raw signals, 1 generated candidate, 41 rejected candidates, 1 valid candidate contract, and 0 rejected candidate contracts.
- Detailed candidate rejection split: 40 expected `PORTFOLIO_GATE_SUPPRESSED` rows and 2 safety-related `NON_CERTIFIED_CANDIDATE_SNAPSHOT` rows.
- Candidate-to-paper lifecycle: 1 valid candidate contract, 1 review-eligible candidate, 1 constructed paper trade, 1 paper position created, and 0 promotion-eligible rows.
- Paper position ledger: 63 positions, 51 open positions, and 12 closed positions.
- Paper position ledger by sleeve: `C2_TREND_EQ_PRIMARY_V1` had 53 positions, 41 open and 12 closed; `C2_CROSS_ASSET_TREND_V1` had 5 open; `C2_MEAN_REVERSION_EQ_V1` had 2 open; `C2_VOL_INCOME_DEFINED_RISK_V1` had 2 open; `C2_OIL_SHOCK_REVERSAL_V1` had 1 open.
- Validation samples: 63 total samples, 12 included closed or resolved outcomes, and 51 excluded samples.
- Sleeve evidence certification: 5 evaluated sleeves, all UNDERPOWERED, 0 positive evidence, 1 BUILDING_SAMPLE, and 4 ZERO_SAMPLE.
- Hypothesis outcome ledger: 9 hypotheses, 12 usable validation samples, all concentrated in `HYP_LARGE_CAP_EQUITY_MOMENTUM_20_60D_V1`; the other 8 hypotheses had 0 usable validation samples.
- Statistical sufficiency: 9 hypotheses, 8 UNDERPOWERED, 1 VALIDATION_READY, and 0 VALIDATED.
- Research quality: 10 hypotheses, 6 UNDERPOWERED, 4 BLOCKED, and 0 ready for capital review.

## Stage Findings

### Hypothesis To Candidate

Flow state: mixed and uneven.

Sleeves flowing through this stage:
- `C2_TREND_EQ_PRIMARY_V1`
- `C2_CROSS_ASSET_TREND_V1`
- `C2_MEAN_REVERSION_EQ_V1`
- `C2_VOL_INCOME_DEFINED_RISK_V1`
- `C2_OIL_SHOCK_REVERSAL_V1`

Sleeves stalled before or at candidate flow:
- `C2_DEFENSIVE_TAIL_V1`: HEALTHY_NO_CANDIDATE / valid no-signal conditions.
- `C2_EVENT_DISLOCATION_V1`: HEALTHY_NO_CANDIDATE on the scorecard, with journal context identifying a data/runtime diagnostic path rather than proven sleeve weakness.
- `C2_INTENT_SIMULATOR_V1`: HEALTHY_NO_CANDIDATE / optional simulator or control path behavior.
- `C2_MARKET_NEUTRAL_SPREAD_V1`: HEALTHY_NO_CANDIDATE / trigger thresholds not met.
- `ehp_macro_calendar_fixture`: NEEDS_DATA / insufficient market or macro-calendar data.

Interpretation: hypothesis-to-candidate flow is not globally broken, but it is not distributed. Four sleeves are healthy-no-candidate or threshold/no-signal states, and one generated macro-calendar path is data-blocked before candidate evidence can exist.

### Candidate To Paper Observation

Flow state: highest same-day numeric drop.

Candidate diagnostics showed 42 raw signals and only 1 generated candidate. The same-day funnel was shaped by 40 expected portfolio-gate suppressions and 2 safety-related non-certified candidate snapshots. After a valid governed contract existed, the candidate-to-paper lifecycle did not show a further same-day drop: 1 valid contract became 1 constructed paper trade and 1 paper position.

Sleeves stalling at this stage:
- `C2_TREND_EQ_PRIMARY_V1`: 40 same-day raw signals, 39 expected portfolio-gate suppressions, and 1 non-certified candidate snapshot bottleneck.
- `C2_VOL_INCOME_DEFINED_RISK_V1`: 1 raw signal blocked by non-certified candidate snapshot.
- `C2_CROSS_ASSET_TREND_V1`: 1 expected portfolio-gate suppression in detailed diagnostics, while the governed candidate contract path also produced the one valid review-only contract.
- `C2_EVENT_DISLOCATION_V1`: related journal evidence showed high candidate inventory in hypothesis evidence but 0 paper positions and 0 usable validation samples, so it remains a paper-observation conversion concern.

Interpretation: the largest same-day conversion drop is raw signal to valid candidate contract, but most of that drop is expected governance suppression rather than candidate-quality failure. The actionable stall is not raw volume; it is governed, certified candidate-to-paper measurability.

### Paper Observation To Outcome

Flow state: highest decision-readiness drop.

The paper position ledger had 63 positions, but 51 remained open and only 12 were closed. Open Paper Position Outcome Follow-Through Review 001 found all 51 high-priority open positions had source exit recommendation HOLD; 47 of 51 had no near-term deterministic closure proximity.

Sleeves stalling at this stage:
- `C2_TREND_EQ_PRIMARY_V1`: 41 open positions and 12 closed positions. This is the only sleeve with closed outcomes, but most of its paper observations remained unresolved.
- `C2_CROSS_ASSET_TREND_V1`: 5 open, 0 closed.
- `C2_MEAN_REVERSION_EQ_V1`: 2 open, 0 closed.
- `C2_VOL_INCOME_DEFINED_RISK_V1`: 2 open, 0 closed.
- `C2_OIL_SHOCK_REVERSAL_V1`: 1 open, 0 closed; generated-hypothesis outcome artifacts identify close condition not met.

Interpretation: this stage contributes most to outcome immaturity because paper observations exist but have not crossed deterministic closure conditions. It is the main reason open positions outnumber included validation samples.

### Outcome To Validation Sample

Flow state: low drop for closed outcomes, high exclusion from open outcomes.

Validation samples showed 63 total samples, 12 included closed or resolved outcomes, and 51 excluded samples. This indicates that closed or resolved outcomes can become included samples, but open paper positions remain excluded.

Sleeves stalling at this stage:
- The four paper-active zero-sample sleeves stalled because their paper observations were open, not because reviewed closed outcomes failed sample inclusion: `C2_CROSS_ASSET_TREND_V1`, `C2_MEAN_REVERSION_EQ_V1`, `C2_VOL_INCOME_DEFINED_RISK_V1`, and `C2_OIL_SHOCK_REVERSAL_V1`.
- `C2_TREND_EQ_PRIMARY_V1` produced all 12 included samples but still had 41 excluded open-position samples.

Interpretation: the validation-sample stage mainly reflects upstream outcome latency. The reviewed evidence does not show a broad closed-outcome-to-sample inclusion failure on 2026-06-03.

### Validation Sample To Evidence Maturity

Flow state: universal evidence-maturity stall.

Sleeve evidence certification marked every evaluated sleeve UNDERPOWERED. Statistical sufficiency showed 8 of 9 hypotheses underpowered, 1 validation-ready, and 0 validated. Research quality showed 0 ready for capital review.

Sleeves stalling at this stage:
- `C2_TREND_EQ_PRIMARY_V1`: BUILDING_SAMPLE but still UNDERPOWERED, with early weak realized evidence.
- `C2_CROSS_ASSET_TREND_V1`: ZERO_SAMPLE and UNDERPOWERED.
- `C2_MEAN_REVERSION_EQ_V1`: ZERO_SAMPLE and UNDERPOWERED.
- `C2_VOL_INCOME_DEFINED_RISK_V1`: ZERO_SAMPLE and UNDERPOWERED.
- `C2_OIL_SHOCK_REVERSAL_V1`: ZERO_SAMPLE and UNDERPOWERED.

Interpretation: this stage contributes most to capital-readiness blockage. Even where samples exist, they are too few, too concentrated, and not positive enough to mature evidence.

## Answers To Review Questions

1. Which stage has the highest drop-off?

Two lenses matter. The highest same-day numeric drop is Candidate conversion: 42 raw signals to 1 generated candidate and 1 valid contract. The highest decision-readiness drop is Paper Observation to Outcome and Validation Sample: 63 paper positions to 12 included samples, with 51 open/excluded.

2. Which stage contributes most to evidence concentration?

Paper Observation and Outcome. `C2_TREND_EQ_PRIMARY_V1` held 53 of 63 paper positions and all 12 closed outcomes. Concentration starts with paper-position depth and is amplified when only that sleeve reaches closed included samples.

3. Which stage contributes most to outcome immaturity?

Paper Observation to Outcome. The dominant condition was 51 open positions, all HOLD in the reviewed high-priority follow-through population, with 47 of 51 showing no near-term deterministic closure proximity.

4. Which stage has the highest leverage if improved?

Candidate to Paper Observation has the highest upstream leverage because it determines whether evidence can become distributed beyond the current trend-equity concentration. Paper Observation to Outcome has the highest immediate leverage because existing open positions are the nearest source of additional validation samples.

5. Which sleeves stall at each stage?

- Hypothesis to Candidate: `C2_DEFENSIVE_TAIL_V1`, `C2_EVENT_DISLOCATION_V1`, `C2_INTENT_SIMULATOR_V1`, `C2_MARKET_NEUTRAL_SPREAD_V1`, and `ehp_macro_calendar_fixture`.
- Candidate to Paper Observation: `C2_TREND_EQ_PRIMARY_V1`, `C2_VOL_INCOME_DEFINED_RISK_V1`, `C2_CROSS_ASSET_TREND_V1`, and event-dislocation-related hypothesis flow.
- Paper Observation to Outcome: `C2_TREND_EQ_PRIMARY_V1`, `C2_CROSS_ASSET_TREND_V1`, `C2_MEAN_REVERSION_EQ_V1`, `C2_VOL_INCOME_DEFINED_RISK_V1`, and `C2_OIL_SHOCK_REVERSAL_V1`.
- Outcome to Validation Sample: primarily the same paper-active open-position sleeves, because open outcomes remain excluded.
- Validation Sample to Evidence Maturity: all evaluated sleeves, because every sleeve remained UNDERPOWERED.

## Bottleneck Ranking

1. Paper Observation to Outcome latency.
Primary cause of current outcome immaturity. It explains the 51 open positions and 51 excluded samples.

2. Candidate to Paper Observation conversion.
Highest upstream leverage for distribution. It determines whether non-trend hypotheses can generate measurable evidence instead of leaving outcome maturity concentrated.

3. Validation Sample to Evidence Maturity.
Primary capital-readiness blocker. Existing included samples are too few, too concentrated, and not mature enough to validate any hypothesis.

4. Hypothesis to Candidate flow.
Selective blocker for dormant, needs-data, threshold, optional simulator, and no-paper-path hypotheses. Important, but not uniformly a failure because some no-candidate states are expected.

5. Outcome to Validation Sample inclusion.
Not the primary independent bottleneck on 2026-06-03. The reviewed drop is mostly explained by open, unresolved outcomes rather than closed outcomes failing inclusion.

## Evidence Flow Map

| Stage | 2026-06-03 state | Main drop-off | Main affected sleeves | Interpretation |
|---|---:|---|---|---|
| Hypothesis | 10 research-quality rows; 6 underpowered, 4 blocked | Blocked/no-paper-path/data states | Defensive Tail, Event Dislocation, Intent Simulator, Market Neutral, Macro fixture | Some hypotheses cannot yet become measurable. |
| Candidate | 42 raw signals, 1 generated candidate, 1 valid contract | 40 expected suppressions, 2 certification bottlenecks | Trend EQ, Vol Income, Cross Asset | Raw volume does not equal valid candidate evidence. |
| Paper Observation | 63 positions | Heavy concentration in one sleeve | Trend EQ dominates with 53 positions | Paper flow exists but is not distributed. |
| Outcome | 12 closed, 51 open | Open positions remain HOLD | All paper-active sleeves, especially Trend EQ | Main outcome immaturity source. |
| Validation Sample | 12 included, 51 excluded | Open outcomes excluded | Trend EQ has all included samples; others zero | Sample flow mirrors outcome closure. |
| Evidence Maturity | 5 sleeves UNDERPOWERED, 0 positive evidence; 0 validated hypotheses | Samples too sparse/concentrated | All evaluated sleeves | No capital-ready evidence. |

## Highest-Leverage Intervention

The highest-leverage intervention is evidence-flow triage, not idea generation.

Near-term: keep read-only deterministic follow-through on existing paper observations, especially the open positions closest to existing deterministic closure conditions and the zero-sample paper-active sleeves.

Upstream: prioritize candidate-to-paper measurability for non-trend sleeves by using existing diagnostics to separate expected no-signal behavior, expected governance suppression, certification bottlenecks, missing data, no-paper-path states, and true conversion defects.

This does not require architecture, rule changes, new candidates, sleeve changes, governance changes, or runtime truth changes.

## Most Important Future Metric

The most important future metric is distributed included validation samples by sleeve and hypothesis.

A useful version of this metric should track:
- Count of sleeves with at least one included validation sample.
- Count of hypotheses with at least one included validation sample.
- Included samples by sleeve, not just aggregate samples.
- Open-to-closed conversion rate by sleeve.
- Candidate-to-paper conversion rate after separating expected governance suppression and certification defects.
- Number of sleeves moving from ZERO_SAMPLE to BUILDING_SAMPLE.

The reason this metric matters: aggregate paper positions and aggregate candidates can grow while evidence remains concentrated, underpowered, or blocked. AEGIS gets stronger only when evidence flows through the whole chain into distributed, included, mature validation samples.

## Final Judgment

The next phase should optimize evidence flow, not idea generation.

The strongest current bottleneck is not lack of hypotheses or search surface. It is that too much evidence stops before becoming closed, included, distributed, mature validation evidence. AEGIS can drown in ideas if it cannot move hypotheses through candidate, paper observation, outcome, validation sample, and evidence maturity.
